UK's NICE recommends use of Cosentyx (secukinumab) in active psoriatic arthritis- Novartis
The UK's National Institute for Health and Care Excellence is supporting use of Cosentyx (secukinumab), from Novartis, alone, or in combination with methotrexate, for adults with active psoriatic arthritis if the person has had a TNF-alpha inhibitor but their disease has stopped responding after the first 12 weeks, and also if TNF-alpha inhibitors are contraindicated but would otherwise be considered. The drug is provided under the conditions of a patient access scheme.
Use should also follow existing NICE guidance psoriatic arthritis treatment with etanercept (Pfizer's Enbrel), infliximab (MSD's Remicade, Napp Pharmaceuticals' Remsima, and Hospira's Inflectra) and adalimumab (AbbVie's Humira).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins